| Pharmaceutical industry sponsorship and research outcome and quality: systematic review J Lexchin, LA Bero, B Djulbegovic, O Clark bmj 326 (7400), 1167-1170, 2003 | 2682 | 2003 |
| Industry sponsorship and research outcome A Lundh, J Lexchin, B Mintzes, JB Schroll, L Bero Cochrane database of systematic reviews, 2017 | 1940 | 2017 |
| The cost of pushing pills: a new estimate of pharmaceutical promotion expenditures in the United States MA Gagnon, J Lexchin Plos medicine 5 (1), e1, 2008 | 717 | 2008 |
| The cost of drug development: a systematic review S Morgan, P Grootendorst, J Lexchin, C Cunningham, D Greyson Health policy 100 (1), 4-17, 2011 | 696 | 2011 |
| Information from pharmaceutical companies and the quality, quantity, and cost of physicians' prescribing: a systematic review GK Spurling, PR Mansfield, BD Montgomery, J Lexchin, J Doust, ... PLoS medicine 7 (10), e1000352, 2010 | 660 | 2010 |
| How does direct-to-consumer advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA B Mintzes, ML Barer, RL Kravitz, K Bassett, J Lexchin, A Kazanjian, ... Cmaj 169 (5), 405-412, 2003 | 427 | 2003 |
| Interactions between physicians and the pharmaceutical industry: what does the literature say? J Lexchin CMAJ: Canadian Medical Association Journal 149 (10), 1401, 1993 | 413 | 1993 |
| Influence of direct to consumer pharmaceutical advertising and patients' requests on prescribing decisions: two site cross sectional survey B Mintzes, ML Barer, RL Kravitz, A Kazanjian, K Bassett, J Lexchin, ... Bmj 324 (7332), 278-279, 2002 | 391 | 2002 |
| Pharmaceutical research and development: what do we get for all that money? DW Light, JR Lexchin Bmj 345, 2012 | 349 | 2012 |
| Physician awareness of drug cost: a systematic review GM Allan, J Lexchin, N Wiebe PLoS medicine 4 (9), e283, 2007 | 330 | 2007 |
| Institutional corruption of pharmaceuticals and the myth of safe and effective drugs DW Light, J Lexchin, JJ Darrow Journal of Law, Medicine & Ethics 41 (3), 590-600, 2013 | 265 | 2013 |
| Drugs in the news: an analysis of Canadian newspaper coverage of new prescription drugs A Cassels, MA Hughes, C Cole, B Mintzes, J Lexchin, JP McCormack Cmaj 168 (9), 1133-1137, 2003 | 264 | 2003 |
| The pharmaceutical industry as a medicines provider D Henry, J Lexchin The Lancet 360 (9345), 1590-1595, 2002 | 261 | 2002 |
| Effects of prescription drug user fees on drug and health services use and on health status in vulnerable populations: a systematic review of the evidence J Lexchin, P Grootendorst International Journal of Health Services 34 (1), 101-122, 2004 | 245 | 2004 |
| Those who have the gold make the evidence: how the pharmaceutical industry biases the outcomes of clinical trials of medications J Lexchin Science and engineering ethics 18, 247-261, 2012 | 195 | 2012 |
| Bigger and better: how Pfizer redefined erectile dysfunction J Lexchin PLoS medicine 3 (4), e132, 2006 | 195 | 2006 |
| Drug promotion: What we know, what we have yet to learn: Reviews of materials in the WHO/HAI database on drug promotion P Norris, A Herxheimer, J Lexchin, P Mansfield Drug promotion: what we know, what we have yet to learn: reviews of …, 2005 | 191* | 2005 |
| Reporting of conflicts of interest in meta-analyses of trials of pharmacological treatments M Roseman, K Milette, LA Bero, JC Coyne, J Lexchin, EH Turner, ... Jama 305 (10), 1008-1017, 2011 | 186 | 2011 |
| What information do physicians receive from pharmaceutical representatives? J Lexchin Canadian Family Physician 43, 941, 1997 | 182 | 1997 |
| Direct-to-consumer advertising of prescription drugs: the evidence says no J Lexchin, B Mintzes Journal of Public Policy & Marketing 21 (2), 194-201, 2002 | 178 | 2002 |
